SCHEMBL4520717

SCHEMBL4520717

CN1CCN(c2ccc(NC(=O)N3CC(c4nc5c(cnn5-c5ccccc5)c(=O)[nH]4)C3)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.49
TYK2 P29597 1/20 0.48
PDE9A O76083 2/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 2/20 0.44
HTT P42858 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPK1 P28482 1/20 0.43
PDE5A O76074 1/20 0.42
PTGS2 P35354 1/20 0.42
PIK3CA P42336 2/20 0.42
MTOR P42345 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CASP3 P42574 1/20 0.42
CASP7 P55210 1/20 0.42
KDR P35968 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4505069 0.91 TSHR (0.48) TSHRTYK2PDE9AALDH1A1HPGD
SCHEMBL4513101 0.91 MAPK1 (0.51) TSHRTYK2PDE9AALDH1A1HPGD
SCHEMBL4510948 0.89 TYK2 (0.53) TSHRTYK2PDE9AALDH1A1HPGD
SCHEMBL4502029 0.86 POLB (0.49) TSHRTYK2PDE9AALDH1A1HPGD
SCHEMBL4514570 0.86 PDE9A (0.61) TSHRTYK2PDE9AALDH1A1HTT
SCHEMBL4512344 0.86 TYK2 (0.48) TSHRTYK2PDE9AALDH1A1HPGD
SCHEMBL4511659 0.86 PDE9A (0.50) TSHRTYK2PDE9AALDH1A1HPGD
SCHEMBL4520709 0.85 PDE9A (0.51) PDE9APDE5APIK3CAMTOR
SCHEMBL4505445 0.84 TYK2 (0.46) TSHRTYK2PDE9AALDH1A1HPGD
SCHEMBL4516468 0.84 TYK2 (0.51) TSHRTYK2PDE9AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases GALAPAGOS NV (BE) 2009-05-28 US claimed
WO-2008055959-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-05-15 WO claimed
US-11166956-B2 Combinations of PDE1 inhibitors and NEP inhibitors INTRA-CELLULAR THERAPIES, INC. (US) 2021-11-09 US disclosed
US-20190275046-A1 NOVEL COMBINATION INTRA-CELLULAR THERAPIES, INC. (US) 2019-09-12 US disclosed
US-10285992-B2 Combinations of PDE1 inhibitors and NEP inhibitors and associated methods INTRA-CELLULAR THERAPIES, INC. (US) 2019-05-14 US disclosed
US-20160038494-A1 NOVEL COMBINATION INTRA-CELLULAR THERAPIES, INC. 2016-02-11 US disclosed
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases GALAPAGOS NV (BE) 2009-05-28 US disclosed
WO-2008055959-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160038494-A1 NOVEL COMBINATION PDE5A, PDE2A, PDE3A TSHR 3757/4885TYK2 4707/4885PDE9A 40/4885
US-10285992-B2 Combinations of PDE1 inhibitors and NEP inhibitors and associated methods PDE5A, PDE3A, PDE2A TSHR 3845/4885TYK2 4749/4885PDE9A 29/4885
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases PDE4A, PDE7B, PDE4B TSHR 4657/4885TYK2 3816/4885PDE9A 13/4885
US-20190275046-A1 NOVEL COMBINATION PDE5A, PDE2A, PDE3A TSHR 3757/4885TYK2 4707/4885PDE9A 40/4885
US-11166956-B2 Combinations of PDE1 inhibitors and NEP inhibitors PDE5A, ECE1, PDE3A TSHR 3893/4885TYK2 4759/4885PDE9A 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.